Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug528 | BMS-986337 Placebo Wiki | 1.00 |
drug909 | Cannabis, Medical Wiki | 1.00 |
drug1640 | Famotidine Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D000070627 | Chronic Traumatic Encephalopathy NIH | 1.00 |
D005879 | Tourette Syndrome NIH | 1.00 |
D001714 | Bipolar Disorder NIH | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D012640 | Seizures NIH | 0.58 |
D006526 | Hepatitis C NIH | 0.58 |
D000690 | Amyotrophic Lateral Sclerosis NIH | 0.50 |
D000755 | Anemia, Sickle Cell NIH | 0.50 |
D016472 | Motor Neuron Disease NIH | 0.50 |
D005356 | Fibromyalgia NIH | 0.45 |
D001927 | Brain Diseases NIH | 0.41 |
D000070642 | Brain Injuries, Traumatic NIH | 0.33 |
D015212 | Inflammatory Bowel Diseases NIH | 0.33 |
D010300 | Parkinsonian NIH | 0.30 |
D001930 | Brain Injuries, NIH | 0.28 |
D059350 | Chronic Pain NIH | 0.27 |
D003424 | Crohn Disease NIH | 0.26 |
D009103 | Multiple Sclerosis NIH | 0.23 |
D012598 | Scoliosi NIH | 0.22 |
D040921 | Stress Disorders, Traumatic NIH | 0.17 |
D014947 | Wounds and Injuries NIH | 0.17 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.16 |
D004194 | Disease NIH | 0.16 |
D013577 | Syndrome NIH | 0.09 |
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100754 | Mania HPO | 0.71 |
HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.50 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001250 | Seizure HPO | 0.45 |
HP:0001298 | Encephalopathy HPO | 0.41 |
HP:0002037 | Inflammation of the large intestine HPO | 0.33 |
HP:0012532 | Chronic pain HPO | 0.27 |
HP:0100280 | Crohn's disease HPO | 0.26 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986337 in healthy participants and in healthy Japanese participants.
Description: PR interval is the time from the onset of the P wave to the start of the QRS complex
Measure: Number of clinically significant changes in ECG parameters: PR interval Time: Up to 51 daysDescription: QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization
Measure: Number of clinically significant changes in ECG parameters: QRS duration Time: Up to 51 daysDescription: QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.
Measure: Number of clinically significant changes in ECG parameters: QTc-interval (Fridericia's) Time: Up to 51 daysDescription: The QT interval is the time from the start of the Q wave to the end of the T wave.
Measure: Number of clinically significant changes in ECG parameters: QT interval Time: Up to 51 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports